An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)

INTRODUCTION: PIPF-002 was a phase 2, multicenter, open-label study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) or other types of pulmonary fibrosis (PF). PIPF-002 terminated after pirfenidone became commercially available in the United States. The goal of PIPF-002 was to cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Gotfried, Mark H., Girod, Carlos E., Antin-Ozerkis, Danielle, Burgess, Tracy, Strombom, Indiana, Stauffer, John L., Kirchgaessler, Klaus-Uwe, Padilla, Maria L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare Communications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967037/
https://www.ncbi.nlm.nih.gov/pubmed/32026243
http://dx.doi.org/10.1007/s41030-018-0053-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967037/
https://www.ncbi.nlm.nih.gov/pubmed/32026243
http://dx.doi.org/10.1007/s41030-018-0053-y

Ejemplares similares